{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:04:05Z","timestamp":1794643445816,"version":"4.9.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,16]],"date-time":"2020-11-16T00:00:00Z","timestamp":1605484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003921","name":"Department of Health, Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003921","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.antiviral.2020.104970","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T07:10:07Z","timestamp":1604560207000},"page":"104970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"special_numbering":"C","title":["Burden of influenza B virus infection and considerations for clinical management"],"prefix":"10.1016","volume":"185","author":[{"given":"Hassan","family":"Zaraket","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C.","family":"Hurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Barr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib2","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3201\/eid2504.181554","article-title":"Reduced susceptibility to neuraminidase inhibitors in influenza B isolate, Canada","volume":"25","author":"Abed","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib3","author":"Alpivab"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jcm8020192","article-title":"Emerging influenza D virus threat: what we know so far!","volume":"8","author":"Asha","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.antiviral.2020.104970_bib5","author":"Avigan"},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib6","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"17","key":"10.1016\/j.antiviral.2020.104970_bib7","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2165\/11641110-000000000-00000","article-title":"The coming era of quadrivalent human influenza vaccines: who will benefit?","volume":"72","author":"Barr","year":"2012","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.antiviral.2020.104970_bib8","doi-asserted-by":"crossref","first-page":"ofz430","DOI":"10.1093\/ofid\/ofz430","article-title":"Pharmacokinetics and pharmacodynamics of conventional-dose vs triple-dose oseltamivir in severely immunocompromised children with influenza","volume":"6","author":"Bautista","year":"2019","journal-title":"Open Forum Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib9","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","article-title":"Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance","volume":"100","author":"Burnham","year":"2013","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib10","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.04623-14","article-title":"Preclinical activity of VX-787, a first-in-class, orally bioavailable inhibitor of the influenza virus polymerase PB2 subunit","volume":"59","author":"Byrn","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104970_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/irv.12575","article-title":"Clinical characteristics and severity of influenza infections by virus type, subtype, and lineage: a systematic literature review","volume":"12","author":"Caini","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"issue":"9","key":"10.1016\/j.antiviral.2020.104970_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222381","article-title":"The epidemiological signature of influenza B virus and its B\/Victoria and B\/Yamagata lineages in the 21st century","volume":"14","author":"Caini","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.antiviral.2020.104970_bib112","author":"CDC"},{"key":"10.1016\/j.antiviral.2020.104970_bib13","author":"CDC"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104970_bib14","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1093\/cid\/cis885","article-title":"Influenza B lineage circulation and hospitalization rates in a subtropical city, Hong Kong, 2000-2010","volume":"56","author":"Chan","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib15","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s10096-020-03835-6","article-title":"Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study","volume":"39","author":"Chen","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib16","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0000000000002528","article-title":"Early administration of oseltamivir within 48 hours after onset of flulike symptoms can reduce the risk of influenza B virus-associated pneumonia in hospitalized pediatric patients with influenza B virus infection","volume":"39","author":"Dai","year":"2020","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104970_bib17","author":"Inavir"},{"issue":"11","key":"10.1016\/j.antiviral.2020.104970_bib18","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.antiviral.2020.104970_bib19","author":"Dectova"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.vaccine.2012.10.084","article-title":"Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials","volume":"31","author":"DiazGranados","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib21","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/jac\/dkv065","article-title":"Influenza viruses with B\/Yamagata- and B\/Victoria-like neuraminidases are differentially affected by mutations that alter antiviral susceptibility","volume":"70","author":"Farrukee","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104970_bib23","article-title":"Effectiveness of trivalent and quadrivalent inactivated vaccines against influenza B in the United States, 2011-2012 to 2016-2017","volume":"2020 Feb 1","author":"Gaglani","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib24","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.2105\/AJPH.2012.301137","article-title":"The burden of influenza B: a structured literature review","volume":"103","author":"Glezen","year":"2013","journal-title":"Am. J. Publ. Health"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104970_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jinf.2012.07.004","article-title":"Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave","volume":"65","author":"Gutierrez-Pizarraya","year":"2012","journal-title":"J. Infect."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","article-title":"Influenza virus polymerase inhibitors in clinical development","volume":"32","author":"Hayden","year":"2019","journal-title":"Curr. Opin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/135965350000500305","article-title":"Oral oseltamivir in human experimental influenza B infection","volume":"5","author":"Hayden","year":"2000","journal-title":"Antivir. Ther."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104970_bib29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib31","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ebiom.2018.12.051","article-title":"Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebo-controlled study","volume":"40","author":"Hershberger","year":"2019","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib32","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/cid\/ciz908","article-title":"Baloxavir marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes","volume":"71","author":"Hirotsu","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","article-title":"Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives","volume":"12","author":"Hurt","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jcv.2015.10.016","article-title":"Characterisation of nosocomial and community-acquired influenza in a large university hospital during two consecutive influenza seasons","volume":"73","author":"Huzly","year":"2015","journal-title":"J. Clin. Virol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib35","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jiac.2013.07.002","article-title":"In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan","volume":"20","author":"Ikematsu","year":"2014","journal-title":"J. Infect. Chemother."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jiac.2019.04.007","article-title":"In vitro neuraminidase inhibitory concentration (IC50) of four neuraminidase inhibitors in the Japanese 2017-18 season: comparison with the 2010-11 to 2016-17 seasons","volume":"25","author":"Ikematsu","year":"2019","journal-title":"J. Infect. Chemother."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib37","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104970_bib39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jiac.2018.01.013","article-title":"Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan","volume":"24","author":"Ishiguro","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.antiviral.2020.104970_bib40","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/B978-0-7020-6285-8.00154-4","article-title":"Antiviral agents against respiratory viruses","author":"Ison","year":"2017","journal-title":"Infectious Diseases"},{"issue":"10","key":"10.1016\/j.antiviral.2020.104970_bib41","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/irv.12522","article-title":"Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region","volume":"12","author":"Jennings","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"issue":"Suppl 1","key":"10.1016\/j.antiviral.2020.104970_bib110","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1093\/ofid\/ofy209.115","volume":"5","author":"Kawaguchi","year":"2018","journal-title":"Open Forum Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib43","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1086\/505868","article-title":"A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons","volume":"43","author":"Kawai","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104970_bib44","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1086\/518385","article-title":"Zanamivir treatment is equally effective for both influenza A and influenza B","volume":"44","author":"Kawai","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/irv.12147","article-title":"Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season","volume":"8","author":"Koseki","year":"2014","journal-title":"Influenza Other Respir. Viruses"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib46","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2217\/fmb.15.120","article-title":"Knowns and unknowns of influenza B viruses","volume":"11","author":"Koutsakos","year":"2016","journal-title":"Future Microbiol."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"11","key":"10.1016\/j.antiviral.2020.104970_bib48","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/molecules21111513","article-title":"Influenza neuraminidase inhibitors: synthetic approaches, derivatives and biological activity","volume":"21","author":"Laborda","year":"2016","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib49","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jinf.2019.07.008","article-title":"Comparative global epidemiology of influenza, respiratory syncytial and parainfluenza viruses, 2010-2015","volume":"79","author":"Lam","year":"2019","journal-title":"J. Infect."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104970_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006749","article-title":"Genome-wide evolutionary dynamics of influenza B viruses on a global scale","volume":"13","author":"Langat","year":"2017","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.antiviral.2020.104970_bib52","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/cid\/cit597","article-title":"A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections","volume":"57","author":"Lee","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib53","doi-asserted-by":"crossref","first-page":"e00352","DOI":"10.1128\/AAC.00352-20","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection","volume":"64","author":"Lim","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib54","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41467-018-08165-y","article-title":"Cross-lineage protection by human antibodies binding the influenza B hemagglutinin","volume":"10","author":"Liu","year":"2019","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058222","article-title":"Surveillance and vaccine effectiveness of an influenza epidemic predominated by vaccine-mismatched influenza B\/Yamagata-lineage viruses in Taiwan, 2011-12 season","volume":"8","author":"Lo","year":"2013","journal-title":"PloS One"},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib56","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1093\/cid\/ciaa023","article-title":"Favipiravir and zanamivir cleared infection with influenza B in a severely immunocompromised child","volume":"71","author":"Lumby","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib57","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1097\/INF.0b013e318217e356","article-title":"A large outbreak of influenza B-associated benign acute childhood myositis in Germany, 2007\/2008","volume":"30","author":"Mall","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104970_bib58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.antiviral.2017.10.021","article-title":"A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment","volume":"148","author":"Marathe","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104970_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antiviral. Res."},{"issue":"10","key":"10.1016\/j.antiviral.2020.104970_bib59","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3201\/eid2510.190607","article-title":"Susceptibility of influenza A, B, C, and D viruses to baloxavir(1)","volume":"25","author":"Mishin","year":"2019","journal-title":"Emerg. Infect. Dis."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40121-019-00271-8","article-title":"Safety, resistance, and efficacy results from a phase IIIb study of conventional- and double-dose oseltamivir regimens for treatment of influenza in immunocompromised patients","volume":"8","author":"Mitha","year":"2019","journal-title":"Infect. Dis. Ther."},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib61","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","article-title":"Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a postmarketing surveillance of more than 3000 patients","volume":"26","author":"Nakazawa","year":"2020","journal-title":"J. Infect. Chemother."},{"key":"10.1016\/j.antiviral.2020.104970_bib62","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"issue":"17","key":"10.1016\/j.antiviral.2020.104970_bib63","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1021\/jm100621s","article-title":"Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses","volume":"53","author":"Oakley","year":"2010","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104970_bib64","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/infdis\/jir861","article-title":"Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection","volume":"205","author":"Paddock","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"42","key":"10.1016\/j.antiviral.2020.104970_bib65","doi-asserted-by":"crossref","first-page":"E8905","DOI":"10.1073\/pnas.1706125114","article-title":"Structures of human-infecting Thogotovirus fusogens support a common ancestor with insect baculovirus","volume":"114","author":"Peng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7159","key":"10.1016\/j.antiviral.2020.104970_bib66","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/bmj.317.7159.660","article-title":"Antiviral drug resistance","volume":"317","author":"Pillay","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.antiviral.2020.104970_bib67","unstructured":"Portsmouth S, Ison MG, Yoshida Y, Shishido T, Hayden FG, Uehara T, editors, 2019. Baloxavir demonstrates clinical and virological efficacy in high-risk patients with influenza B infections (CAPSTONE-2 Study). ECCMID; 13\u201316 April 2019, Amsterdam, Netherlands."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib68","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12879-019-4621-z","article-title":"Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017","volume":"19","author":"Puzelli","year":"2019","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib69","author":"Rapivab"},{"key":"10.1016\/j.antiviral.2020.104970_bib70","author":"Relenza"},{"key":"10.1016\/j.antiviral.2020.104970_bib71","author":"Relenza"},{"issue":"7","key":"10.1016\/j.antiviral.2020.104970_bib72","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0200849","article-title":"Influenza A\/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance","volume":"13","author":"Roosenhoff","year":"2018","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.antiviral.2020.104970_bib73","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/cid\/ciz939","article-title":"Viral kinetics and resistance development in children treated with neuraminidase inhibitors: the Influenza Resistance Information Study (IRIS)","volume":"71","author":"Roosenhoff","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","article-title":"Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983","volume":"175","author":"Rota","year":"1990","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib75","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhin.2018.06.004","article-title":"Molecular characterization of a nosocomial outbreak of influenza B virus in an acute care hospital setting","volume":"101","author":"Sansone","year":"2019","journal-title":"J. Hosp. Infect."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1620\/tjem.214.113","article-title":"Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan","volume":"214","author":"Sato","year":"2008","journal-title":"Tohoku J. Exp. Med."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib77","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1750-2659.2008.00063.x","article-title":"The use of oseltamivir during an influenza B outbreak in a chronic care hospital","volume":"3","author":"Seale","year":"2009","journal-title":"Influenza Other Respir. Viruses"},{"key":"10.1016\/j.antiviral.2020.104970_bib78","doi-asserted-by":"crossref","first-page":"104562","DOI":"10.1016\/j.antiviral.2019.104562","article-title":"New antibody-based prevention and treatment options for influenza","volume":"170","author":"Sedeyn","year":"2019","journal-title":"Antivir. Res."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib79","doi-asserted-by":"crossref","first-page":"e20172918","DOI":"10.1542\/peds.2017-2918","article-title":"Influenza-associated pediatric deaths in the United States, 2010-2016","volume":"141","author":"Shang","year":"2018","journal-title":"Pediatrics"},{"issue":"2544","key":"10.1016\/j.antiviral.2020.104970_bib80","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1126\/science.98.2544.307","article-title":"Isolation and characterization of influenza virus b (Lee strain)","volume":"98","author":"Sharp","year":"1943","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.antiviral.2020.104970_bib81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1021\/acsinfecdis.7b00142","article-title":"The next wave of influenza drugs","volume":"3","author":"Shaw","year":"2017","journal-title":"ACS Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib82","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.antiviral.2009.10.022","article-title":"Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing","volume":"85","author":"Sheu","year":"2010","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib83","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/irv.12296","article-title":"Case series of rash associated with influenza B in school children","volume":"9","author":"Skowronski","year":"2015","journal-title":"Influenza Other Respir. Viruses"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/cid\/ciu269","article-title":"Comparing clinical characteristics between hospitalized adults with laboratory-confirmed influenza A and B virus infection","volume":"59","author":"Su","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib85","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/509925","article-title":"Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children","volume":"44","author":"Sugaya","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib86","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1086\/589748","article-title":"Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children","volume":"47","author":"Sugaya","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/5584_2017_79","article-title":"Benign acute childhood myositis during influenza B outbreak","volume":"1039","author":"Szenborn","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"issue":"4","key":"10.1016\/j.antiviral.2020.104970_bib88","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/21645515.2015.1111494","article-title":"A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries","volume":"12","author":"Tafalla","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.antiviral.2020.104970_bib89","doi-asserted-by":"crossref","first-page":"104718","DOI":"10.1016\/j.antiviral.2020.104718","article-title":"Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018","volume":"175","author":"Takashita","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104970_bib90","author":"Tamiflu"},{"key":"10.1016\/j.antiviral.2020.104970_bib91","author":"Tamiflu"},{"issue":"3","key":"10.1016\/j.antiviral.2020.104970_bib92","doi-asserted-by":"crossref","first-page":"e20154643","DOI":"10.1542\/peds.2015-4643","article-title":"Hospitalization for influenza A versus B","volume":"138","author":"Tran","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2020.104970_bib93","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1741-7015-11-153","article-title":"Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis","volume":"11","author":"Tricco","year":"2013","journal-title":"BMC Med."},{"issue":"6","key":"10.1016\/j.antiviral.2020.104970_bib94","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.antiviral.2020.104970_bib95","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2217\/fmb.15.65","article-title":"Influenza B viruses: not to be discounted","volume":"10","author":"van de Sandt","year":"2015","journal-title":"Future Microbiol."},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib96","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/infdis\/jiv375","article-title":"Outcomes and susceptibility to neuraminidase inhibitors in individuals infected with different influenza B lineages: the Influenza Resistance Information Study","volume":"213","author":"van der Vries","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104970_bib97","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.05055","article-title":"The contrasting phylodynamics of human influenza B viruses","volume":"4","author":"Vijaykrishna","year":"2015","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.antiviral.2020.104970_bib98","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1073\/pnas.1916585116","article-title":"Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity","volume":"117","author":"Virk","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6428","key":"10.1016\/j.antiviral.2020.104970_bib99","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational design of potent sialidase-based inhibitors of influenza virus replication","volume":"363","author":"von Itzstein","year":"1993","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.antiviral.2020.104970_bib100","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jama.285.6.748","article-title":"Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial","volume":"285","author":"Welliver","year":"2001","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.antiviral.2020.104970_bib101","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104970_bib102","author":"WHO"},{"key":"10.1016\/j.antiviral.2020.104970_bib103","author":"WHO"},{"key":"10.1016\/j.antiviral.2020.104970_bib104","author":"Xofluza"},{"issue":"1\u20132","key":"10.1016\/j.antiviral.2020.104970_bib105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virusres.2004.02.013","article-title":"Reassortment and evolution of current human influenza A and B viruses","volume":"103","author":"Xu","year":"2004","journal-title":"Virus Res."},{"issue":"12","key":"10.1016\/j.antiviral.2020.104970_bib106","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jiac.2017.07.014","article-title":"Outbreaks of influenza B infection and pneumococcal pneumonia at a mental health facility in Japan","volume":"23","author":"Yamazaki","year":"2017","journal-title":"J. Infect. Chemother."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib107","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3201\/eid2408.180063","article-title":"Variation in influenza B virus epidemiology by lineage, China","volume":"24","author":"Yang","year":"2018","journal-title":"Emerg. Infect. Dis."},{"issue":"8","key":"10.1016\/j.antiviral.2020.104970_bib108","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/INF.0000000000002748","article-title":"Baloxavir marboxil 2% granules in Japanese children with influenza: an open-label phase 3 study","volume":"39","author":"Yokoyama","year":"2020","journal-title":"Pediatr. Infect. Dis. J."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:05Z","timestamp":1759062725000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220303843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":108,"alternative-id":["S0166354220303843"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104970","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of influenza B virus infection and considerations for clinical management","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104970"}}